Nilsson T, Bäck O
Clin Exp Immunol. 1985 Apr;60(1):178-82.
An enzyme linked differential antibody immunosorbent assay for the quantitation of the C1s-C1 inhibitor complex has been developed. A study of the assays' performance under various conditions has shown that before use in the assay, it is imperative to remove competing forms of C1s from the samples to be tested. This is conveniently achieved in human plasma or serum by polyethylene glycol precipitation of the C1qrs, since the C1s-C1 inhibitor complex remains soluble and can be assayed in the supernatant solution. The detection limit of the assay in the plasma milieu is 0.1 mg/l, and the concentrations of the C1s-C1 inhibitor complex were found to be 1 mg/l in citrated plasma and 2 mg/l in serum. Activation of the fibrinolytic system in vivo does not seem to result in any appreciable C1 activation, since there was no concomitant major change in the plasma concentration of the C1s-C1 inhibitor complex.
已开发出一种用于定量C1s-C1抑制剂复合物的酶联差异抗体免疫吸附测定法。对该测定法在各种条件下的性能研究表明,在用于测定之前,必须从待测试样品中去除竞争性形式的C1s。这在人血浆或血清中可通过C1qrs的聚乙二醇沉淀方便地实现,因为C1s-C1抑制剂复合物仍可溶,并且可以在上清液中进行测定。该测定法在血浆环境中的检测限为0.1mg/l,发现柠檬酸盐血浆中C1s-C1抑制剂复合物的浓度为1mg/l,血清中为2mg/l。体内纤维蛋白溶解系统的激活似乎不会导致任何明显的C1激活,因为C1s-C1抑制剂复合物的血浆浓度没有随之发生重大变化。